Thursday, March 23, 2023 11:10:41 PM
I think Jared’s comments on the CC regarding below were most interesting!
“On the Q2 2022 earnings call, we discussed that we were exploring an investigational new drug pathway through the FDA. On our Q3 call, we further discussed the reasons why and how we could do this on a capital-free basis through potential partnering. Charlotte's Web's unique advantage lies in its intellectual property, including 7 hemp patents, safety and toxicology studies, GMP quality control systems and a state-of-the-art manufacturing and distribution facility.
Our IP can be licensed into a biotech partnership leveraging a clinical science and regulatory team to seek an IND and navigate clinical trials to, ultimately, create a botanical drug. The CBD market is estimated at $5 billion today with approximately $1 billion from Epidiolex, the only FDA-approved CBD drug to date. By partnering on an IND path, we provide risk-mitigated upside to our shareholders by unlocking IP value created since the inception of the company and leveraging our core strengths.
We are progressing with speed on this strategy, and we look forward to updating deeper as this leg unfolds.”
“On the Q2 2022 earnings call, we discussed that we were exploring an investigational new drug pathway through the FDA. On our Q3 call, we further discussed the reasons why and how we could do this on a capital-free basis through potential partnering. Charlotte's Web's unique advantage lies in its intellectual property, including 7 hemp patents, safety and toxicology studies, GMP quality control systems and a state-of-the-art manufacturing and distribution facility.
Our IP can be licensed into a biotech partnership leveraging a clinical science and regulatory team to seek an IND and navigate clinical trials to, ultimately, create a botanical drug. The CBD market is estimated at $5 billion today with approximately $1 billion from Epidiolex, the only FDA-approved CBD drug to date. By partnering on an IND path, we provide risk-mitigated upside to our shareholders by unlocking IP value created since the inception of the company and leveraging our core strengths.
We are progressing with speed on this strategy, and we look forward to updating deeper as this leg unfolds.”
Recent CWBHF News
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/06/2026 09:07:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:32:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:31:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 06:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 11:18:49 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/01/2026 11:03:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 09:30:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 09:29:45 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2026 11:08:26 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 11:07:30 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 11:07:11 AM
- Charlotte's Web Reports 2025 Fourth Quarter and Full Year Financial Results • PR Newswire (US) • 03/31/2026 11:07:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 10:46:21 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/31/2026 10:45:01 AM
- Charlotte's Web Announces Transaction with BAT: Debenture Conversion and US$10M Equity Investment to Strengthen Balance Sheet • PR Newswire (US) • 03/31/2026 02:59:00 AM
- Charlotte's Web 2025 Fourth Quarter and Year-End Earnings Call and Webcast Notice • PR Newswire (US) • 03/24/2026 01:15:00 PM
- Charlotte's Web Welcomes New CMS Guidance, Advancing Access to Eligible Full‑Spectrum Hemp Products • PR Newswire (US) • 03/21/2026 01:53:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2026 03:19:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 12:14:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:07:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/21/2025 12:15:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2025 07:34:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2025 08:08:43 PM
